Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus EMFLAZA.
DEXASPORIN vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid